Immunic, Inc. IMUX · Stock Open Immunic, Inc. in new tab
Immunic, Inc. Analysis (IMUX)
Is Immunic, Inc. a good investment? Immunic, Inc. (IMUX) is currently trading at 14.10 USD. Market analysts have a consensus price target of 41.90 USD. This suggests a potential upside from current levels.
Earnings Schedule: Immunic, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -3.63.
Investor FAQ
Does Immunic, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Immunic, Inc.?
Immunic, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -4.77.
Company Profile
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
| Split Date | Split Ratio to 1 |
|---|---|
| April 15, 2019 | 0.030000 |
| April 27, 2026 | 0.100000 |
Community Discussion